Milestone Pharmaceuticals Inc (MIST) NPV

Sell:$1.27Buy:$1.28$0.01 (0.40%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.27
Buy:$1.28
Change:$0.01 (0.40%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$1.27
Buy:$1.28
Change:$0.01 (0.40%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Key people

Joseph Oliveto
President, Chief Executive Officer, Director
Amit Hasija
Chief Financial Officer, Executive Vice President of Corporate Development
Jeffrey Nelson
Chief Operating Officer
David Bharucha
Chief Medical Officer
Lorenz Muller
Chief Commercial Officer
Robert James Wills
Non-Executive Independent Chairman of the Board
Seth H. Z. Fischer
Director
Joeseph C. Papa
Director
Stuart Duty
Independent Director
Lisa M. Giles
Independent Director
Click to see more

Key facts

  • EPIC
    MIST
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA59935V1076
  • Market cap
    $61.89m
  • Employees
    33
  • Shares in issue
    53.35m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.